{
    "clinical_study": {
        "@rank": "75379", 
        "arm_group": {
            "arm_group_label": "Ilaprazole", 
            "arm_group_type": "Experimental", 
            "description": "Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.\nAfter 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed"
        }, 
        "brief_summary": {
            "textblock": "Ilaprazole is a novel proton pump inhibitor and metabolized by CYP3A4 and 2C19. Thus genetic\n      polymorphisms of CYP3A4 and 2C19 may have effect on the pharmacokinetics and\n      pharmacodynamics of Ilaprazole."
        }, 
        "brief_title": "Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "Effects of genetic polymorphisms on the pharmacokinetics or pharmacodynamics were measured\n      in healthy Korean volunteers"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healthy adult volunteer between 20 and 45 years of age and within 20% of ideal body\n             weight\n\n          -  No congenital or acquired chronic disease\n\n          -  appropriate for the study judging from examinations (hematology, chemistry,\n             urinalysis and so on), vital sign and ECG results\n\n          -  sign the informed consent form prior to study participation\n\n        Exclusion Criteria:\n\n          -  received any metabolizing enzymes or transporters inducing or inhibiting drugs like\n             barbiturates within 1 month prior to the date of first drug administration\n\n          -  history of hypersensitivity against drugs or clinically significant allergic diseases\n\n          -  abnormal laboratory results\n\n          -  positive result for helicobacter pylori infection from the Urea Breath Test\n\n          -  alcohol or drug abuser\n\n          -  pregnant or lactating\n\n          -  donated whole blood within 60days prior to the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 6, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688544", 
            "org_study_id": "08-112"
        }, 
        "intervention": {
            "arm_group_label": "Ilaprazole", 
            "description": "Ilaprazole 10 mg for 7 days", 
            "intervention_name": "Ilaprazole", 
            "intervention_type": "Drug", 
            "other_name": [
                "2-[(4methoxy-3-methyl)-2-pyridinyl] methylsulfinyl-", 
                "5-(1H-pyrrol-1yl)-1H-benzimidazole"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Benzimidazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ilaprazole", 
            "Intragastric pH", 
            "Serum Gastrin", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "September 19, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "614-735"
                }, 
                "name": "Inje University Busan Paik Hoapital Clinical Trial Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study to Evaluate the Effect of CYP Polymorphism and Gender on the Pharmacokinetics and Pharmacodynamics of Ilaprazole After Multiple Dosing", 
        "overall_official": {
            "affiliation": "Inje University", 
            "last_name": "JaeGook Shin, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "24 hour intragastric ph", 
            "safety_issue": "No", 
            "time_frame": "After 7 days dosing of Ilaprazole 10 mg"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688544"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Inje University", 
            "investigator_full_name": "Jae-Gook Shin", 
            "investigator_title": "Department of Pharmacology and Pharmacogenomics Research Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic parameters (Cmax, AUC) of Ilaprazole and its metabolite", 
                "safety_issue": "No", 
                "time_frame": "After 7 days dosing of Ilaprazole"
            }, 
            {
                "measure": "Serum Gastrin level", 
                "safety_issue": "No", 
                "time_frame": "After 7 days dosing of Ilaprazole"
            }
        ], 
        "source": "Inje University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Inje University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}